Multiple sclerosis: current treatment algorithms

Current Opinion in Neurology - Tập 24 Số 3 - Trang 230-237 - 2011
Jordi Río1, Manuel Comabella, Xavier Montalbán
1Unitat de Neuroimmunologia Clínica, Centre d'esclerosi múltiple de Catalunya, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [email protected]

Tóm tắt

Từ khóa


Tài liệu tham khảo

1993, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial., Neurology, 43, 655, 10.1212/WNL.43.4.655

Johnson, 1995, Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial, Neurology, 45, 1268, 10.1212/WNL.45.7.1268

1998, Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis., Lancet, 352, 1498, 10.1016/S0140-6736(98)03334-0

1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis., Ann Neurol, 39, 285, 10.1002/ana.410390304

Brown, 2007, How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?, Neurology, 69, 1498, 10.1212/01.wnl.0000271884.11129.f3

Trapp, 1998, Axonal transection in the lesions of multiple sclerosis, N Eng J Med, 338, 278, 10.1056/NEJM199801293380502

Comi, 2001, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, Lancet, 357, 1576, 10.1016/S0140-6736(00)04725-5

Jacobs, 2000, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group, N Engl J Med, 343, 898, 10.1056/NEJM200009283431301

Kappos, 2006, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, 67, 1242, 10.1212/01.wnl.0000237641.33768.8d

Comi, 2009, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial, Lancet, 374, 1503, 10.1016/S0140-6736(09)61259-9

Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, 362, 387, 10.1056/NEJMoa0909494

Cohen, 2010, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N Engl J Med, 362, 402, 10.1056/NEJMoa0907839

Giovannoni, 2010, A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N Engl J Med, 362, 416, 10.1056/NEJMoa0902533

1998, European Study Group on interferon beta-1b in secondary progressive MS., Lancet, 352, 1491

2001, Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results., Neurology, 56, 1496, 10.1212/WNL.56.11.1496

Hartung, 2002, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind randomized multicenter trial, Lancet, 360, 2018, 10.1016/S0140-6736(02)12023-X

Paul, 2007, Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 78, 198, 10.1136/jnnp.2006.091033

Polman, 2006, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 354, 899, 10.1056/NEJMoa044397

Rudick, 2006, Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N Engl J Med, 354, 911, 10.1056/NEJMoa044396

Kappos, 2007, Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring, Lancet Neurol, 6, 431, 10.1016/S1474-4422(07)70078-9

Costello, 2007, Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice, Curr Opin Neurol, 20, 281, 10.1097/WCO.0b013e328122de1b

Freedman, 2009, Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command, Curr Med Res Opin, 25, 2459, 10.1185/03007990903158364

Freedman, 2004, Treatment optimization in multiple sclerosis, Can J Neurol Sci, 31, 157, 10.1017/S0317167100053804

2004, Treatment optimization in multiple sclerosis: report of an international consensus meeting., Eur J Neurol, 11, 43, 10.1046/j.1351-5101.2003.00711.x

Freedman, 2008, Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: analysis of the PRISMS study, Mult Scler, 14, 1234, 10.1177/1352458508093892

Karussis, 2006, A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting, Eur J Neurol, 13, 61, 10.1111/j.1468-1331.2006.01147.x

Río, 2009, Predicting responders to therapies for multiple sclerosis, Nat Rev Neurol, 5, 553, 10.1038/nrneurol.2009.139

Sormani, 2007, A composite score to predict short-term disease activity in patients with relapsing–remitting MS, Neurology, 69, 1230, 10.1212/01.wnl.0000276940.90309.15

Río, 2009, Measures in the first year of therapy predict the response to interferon beta in MS, Mult Scler, 15, 848, 10.1177/1352458509104591

Durelli, 2002, Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN), Lancet, 359, 1453, 10.1016/S0140-6736(02)08430-1

O'Connor, 2009, 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study, Lancet Neurol, 8, 889, 10.1016/S1474-4422(09)70226-1

Mikol, 2008, Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial, Lancet Neurol, 7, 903, 10.1016/S1474-4422(08)70200-X

Gajofatto, 2009, Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis, Mult Scler, 15, 50, 10.1177/1352458508096687

Wiendl, 2008, Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations, J Neurol, 255, 1449, 10.1007/s00415-008-0061-1

Le Page, 2009, Long-term experience with induction treatment regimens in multiple sclerosis, J Neurol Sci, 277, S46, 10.1016/S0022-510X(09)70013-9